What is the advantage of designing an antiviral drug that inhibits the very early or very late steps of viral replication?

A) The antiviral drug will be in higher concentrations in the body.
B) The antiviral drug does not need to enter the cell to work.
C) The antiviral drug will have a higher binding affinity for the viral protein.
D) The antiviral drug has a higher chance of inhibiting the virus infection.
E) The antiviral drug will be more easily eliminated from the body.